United Therapeutics Corporation
United Therapeutics Announces Record Third Quarter 2025 Financial Results
Summary
On October 29, 2025, United Therapeutics Corporation announced its record financial results for the third quarter of 2025, reporting a 7% year-over-year increase in total revenues to $799.5 million. Net income increased by 10% to $338.7 million, driven by growth in key products such as Tyvaso and Orenitram. The company also announced an accelerated share repurchase agreement to repurchase $2.0 billion of its common stock.
Profitelligence Alerts
Get alerts for UTHR
Be first to know when United Therapeutics Corporation files with the SEC.
Filing Categories
Advertisement
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.
Official SEC Documents
Advertisement